Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 8/20 | 0.48 |
| ▸ | NPC1 | O15118 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714246 | 1.00 | MAPT (0.48) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6713993 | 0.91 | MAPT (0.48) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6715694 | 0.83 | RAB9A (0.52) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6716824 | 0.80 | MAPT (0.49) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6718752 | 0.80 | MAPT (0.49) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6714168 | 0.80 | MEN1 (0.56) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6714162 | 0.80 | MEN1 (0.56) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6717674 | 0.79 | RAB9A (0.47) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6716242 | 0.78 | KMT2A (0.44) | MAPTRAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL6723757 | 0.78 | MAPT (0.48) | MAPTRAB9ANPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | claimed |
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | MAPT 427/4885RAB9A 2094/4885NPC1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.